Colonization with antibiotic resistant bacteria in communities and hospitals across six countries, including Bangladesh, Botswana, Chile, Guatemala, India, and Kenya.

Publication date: Jul 01, 2025

The recognized burden of antimicrobial resistance (AR) is greatest in low- and middle-income countries (LMICs), but limitations in surveillance preclude accurate estimates of AR. We aimed to evaluate colonization in communities and hospitals across six LMICs for two clinically-important pathogens: extended-spectrum cephalosporin-resistant Enterobacterales (ESCrE) and carbapenem-resistant Enterobacterales (CRE). Participants in hospitals and communities provided rectal swabs or stool samples for ESCrE and CRE identification. Isolates recovered from selective agars underwent confirmatory identification and antibiotic susceptibility testing (AST) using Vitek 2, MALDI-TOF, and/or disc diffusion testing. ESCrE and CRE were defined based on established breakpoints of phenotypic resistance to third-generation cephalosporins and carbapenems, respectively, to calculate prevalence of colonization. Community prevalence estimates were weighted to account for sampling design differences. A total of 10,139 participants across the 6 countries provided samples; 63% were females with a median age of 35 years (range: 0-99). Colonization with ESCrE in hospitals was high in all sites (range 34-84%). In communities, ESCrE colonization ranged from 22 to 77%. Prevalence of CRE colonization in hospitals ranged from 7 to 36% and in communities ranged from

Open Access PDF

Concepts Keywords
Antibiotic Adolescent
Botswana Adult
Chile Aged
Females Aged, 80 and over
Kenya Anti-Bacterial Agents
Anti-Bacterial Agents
Antimicrobial resistance
Bangladesh
Carbapenems
Carbapenems
Child
Child, Preschool
Colonization
COVID-19
Drug Resistance, Bacterial
Enterobacteriaceae
Enterobacteriaceae Infections
Epidemiologic trends
Female
Guatemala
Hospitals
Humans
India
Infant
Infant, Newborn
Kenya
Male
Microbial Sensitivity Tests
Middle Aged
Prevalence
Surveillance
Young Adult

Semantics

Type Source Name
disease IDO bacteria
disease IDO susceptibility
disease MESH COVID 19
disease MESH infectious disease
pathway REACTOME Infectious disease
disease MESH infections
drug DRUGBANK Coenzyme M
disease MESH healthcare associated infections
disease IDO infection
disease IDO pathogen
disease IDO antibiotic resistance
disease IDO country
disease MESH neutropenia
disease MESH bleeding
drug DRUGBANK Ceftazidime
drug DRUGBANK Ceftriaxone
drug DRUGBANK Cefotaxime
drug DRUGBANK Ertapenem
drug DRUGBANK Meropenem
drug DRUGBANK Doripenem
drug DRUGBANK Imipenem
disease IDO site
disease MESH Enterobacteriaceae Infections

Original Article

(Visited 1 times, 1 visits today)